IFLR1000

Genmab Nasdaq IPO

16/7/2019
IPO
Select tab

$ 506 million

Completed

16/7/2019

Overview:

  • Genmab, a Danish biotechnology company, has undertaken its Nasdaq IPO.
  • The firm raised $506 million selling 28.5 million American depository receipts (ADRs) at $17.75 a share.

Prin Shasiharan - Researcher

Jurisdictions:

United States
Denmark

Deal type:

IPO

Practice area:

Capital markets : Equity

Industry sector:

Pharmaceuticals and life sciences

Firms:
Bech-Bruun

Party: Bank of America Merrill Lynch (Underwriter)

Party: Morgan Stanley (Underwriter)

Party: Jefferies Financial (Underwriter)

Party: Guggenheim Securities (Underwriter)

Party: RBC Capital Markets (Underwriter)

Party: Danske Markets (Underwriter)

Party: HC Wainwright (Underwriter)

Party: Kempen & Co (Underwriter)

Lawyers: David Moalem, Steen Jensen

Kromann Reumert

Party: Genmab (Issuer)

Lawyer: Christina Bruun Geertsen

Latham & Watkins

Party: Bank of America Merrill Lynch (Underwriter)

Party: Morgan Stanley (Underwriter)

Party: Jefferies Financial (Underwriter)

Party: Guggenheim Securities (Underwriter)

Party: RBC Capital Markets (Underwriter)

Party: Danske Bank (Underwriter)

Party: HC Wainwright (Underwriter)

Party: Kempen & Co (Underwriter)

Shearman & Sterling

Party: Genmab (Issuer)

Lawyer: Harald Halbhuber

Related deals